PEPTRON, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30,600 KRW | +0.99% |
|
+8.32% | -23.98% |
| 2023 | Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal | MT |
| 2023 | Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 5.81B 4.28M 357M | Sales 2023 | 3.34B 2.46M 205M | Capitalization | 830B 611M 50.99B |
|---|---|---|---|---|---|
| Net income 2022 | -15.06B -11.09M -925M | Net income 2023 | -15.92B -11.72M -978M | EV / Sales 2022 | 25.8 x |
| Net cash position 2022 | 8.02B 5.9M 492M | Net Debt 2023 | 4.15B 3.05M 255M | EV / Sales 2023 | 250 x |
| P/E ratio 2022 |
-10.5
x | P/E ratio 2023 |
-52
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.67% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.99% | ||
| 1 week | +8.32% | ||
| Current month | +5.52% | ||
| 1 month | +19.53% | ||
| 3 months | +31.33% | ||
| 6 months | +9.68% | ||
| Current year | -23.98% |
1 week
29 600.00
32 000.00
1 month
21 750.0032 000.00
Current year
21 100.0041 750.00
1 year
7 340.0047 150.00
3 years
7 050.0047 150.00
5 years
7 050.0047 150.00
10 years
7 050.0047 150.00
| Managers | Title | Age | Since |
|---|---|---|---|
Min-Ho Song
CEO | Chief Executive Officer | 63 | 30/21/30 |
Ho-Il Choi
CEO | Chief Executive Officer | 58 | 21/97/21 |
Seung-Gu Jang
DFI | Director of Finance/CFO | 58 | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ho-Il Choi
CEO | Chief Executive Officer | 58 | 21/97/21 |
Seung-Gu Jang
DFI | Director of Finance/CFO | 58 | 01/99/01 |
Young-Go Jung
BRD | Director/Board Member | 49 | 31/14/31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.34% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 30,600 | +0.99% | 666,430 |
| 02/24/02 | 30,300 | +4.48% | 945,600 |
| 30/24/30 | 29,000 | +2.65% | 379,654 |
End-of-day quote Korea S.E., May 03, 2024
More quotes
Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.98% | 465M | |
| +9.15% | 106B | |
| -1.08% | 104B | |
| +6.93% | 23.25B | |
| -11.55% | 22.5B | |
| -7.26% | 18.7B | |
| -37.08% | 17.95B | |
| -9.91% | 16.99B | |
| +7.55% | 14.26B | |
| +40.04% | 12.76B |
- Stock Market
- Equities
- A087010 Stock